MedTrace Logo

Ondansetron for the Treatment of Methamphetamine Dependence - 1

NCT00040053 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 154

Last updated 2017-01-12

No results posted yet for this study

Summary

The purpose of this study is to assess ondansetron for the treatment of methamphetamine dependence.

Conditions

  • Amphetamine-Related Disorders

Interventions

DRUG

Ondansetron

Sponsors & Collaborators

  • University of Texas

    collaborator OTHER

  • National Institute on Drug Abuse (NIDA)

    lead NIH

Principal Investigators

  • Thomas Newton, M.D. · National Institute on Drug Abuse (NIDA)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-06-30
Completion
2004-02-29

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00040053 on ClinicalTrials.gov